CN118059201A - Anti-inflammatory medicinal effect application of honey refining type fritillary and loquat syrup preparation - Google Patents
Anti-inflammatory medicinal effect application of honey refining type fritillary and loquat syrup preparation Download PDFInfo
- Publication number
- CN118059201A CN118059201A CN202410144238.5A CN202410144238A CN118059201A CN 118059201 A CN118059201 A CN 118059201A CN 202410144238 A CN202410144238 A CN 202410144238A CN 118059201 A CN118059201 A CN 118059201A
- Authority
- CN
- China
- Prior art keywords
- honey
- parts
- fritillary
- loquat
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000009008 Eriobotrya japonica Nutrition 0.000 title claims abstract description 62
- 241001092070 Eriobotrya Species 0.000 title claims abstract description 59
- 235000020357 syrup Nutrition 0.000 title claims abstract description 59
- 239000006188 syrup Substances 0.000 title claims abstract description 59
- 235000012907 honey Nutrition 0.000 title claims abstract description 46
- 241000935235 Fritillaria meleagris Species 0.000 title claims abstract description 43
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 30
- 238000007670 refining Methods 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 230000007721 medicinal effect Effects 0.000 title description 3
- 244000269722 Thea sinensis Species 0.000 claims abstract description 20
- 235000009569 green tea Nutrition 0.000 claims abstract description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 241001547127 Fritillaria cirrhosa Species 0.000 claims abstract description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 7
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 7
- 229940041616 menthol Drugs 0.000 claims abstract description 7
- 244000164480 Curcuma aromatica Species 0.000 claims description 15
- 235000003398 Curcuma aromatica Nutrition 0.000 claims description 15
- 210000000265 leukocyte Anatomy 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 6
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 24
- 206010061218 Inflammation Diseases 0.000 description 14
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 201000007100 Pharyngitis Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000016150 acute pharyngitis Diseases 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 235000012754 curcumin Nutrition 0.000 description 7
- 229940109262 curcumin Drugs 0.000 description 7
- 239000004148 curcumin Substances 0.000 description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001644295 Fritillaria przewalskii Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 244000061508 Eriobotrya japonica Species 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241001219085 Cyclopia Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Insects & Arthropods (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Husbandry (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an anti-inflammatory drug effect application of a honey refining type fritillary and loquat syrup preparation, which comprises the following components in parts by mass: 10-20 parts of honey, 60-80 parts of fritillaria cirrhosa, 200-300 parts of loquat leaf, 60-80 parts of platycodon grandiflorum, 0.4-1.5 parts of menthol, 40-60 parts of radix curcumae, 20-30 parts of green tea and 30-40 parts of liquorice; the honey-refined fritillary and loquat syrup has obvious anti-inflammatory effect, can effectively inhibit the generation and release of inflammatory factors, reduces inflammatory symptoms, has no toxic or side effect, and has good taste and convenient eating.
Description
Technical Field
The invention relates to the technical field of health care and traditional Chinese medicines, in particular to an anti-inflammatory drug effect application of a honey-refined fritillary and loquat syrup preparation.
Background
The syrup is a pure Chinese medicinal preparation of oral syrup for treating cough with yellow phlegm or unsmooth spitting phlegm, sore throat, chest pain, cold cough, chronic bronchitis and other symptoms caused by wind-heat affecting the lung and internal depression transforming into fire, and has stable quality and definite curative effect, which is a common medicinal preparation for treating the above symptoms clinically and at home through years of clinical verification. Other similar oral preparations, such as water-paste pills, tablets, and the like, have different therapeutic effects, basically the same medicinal effect and no obvious difference.
Inflammation is a reaction of the human immune system to external stimuli, but excessive inflammatory reactions can lead to tissue damage and disease. Currently, there are many anti-inflammatory drugs on the market, but most drugs have side effects and drug resistance problems. While the main effect of fritillary and loquat syrup is to relieve cough, the efficacy of diminishing inflammation is still to be further excavated.
Therefore, a technical scheme for providing the anti-inflammatory effect of honey-refined fritillary and loquat syrup is needed.
Disclosure of Invention
In view of the above, the application provides an anti-inflammatory drug effect application of honey-refined fritillary and loquat syrup, which is used for solving the problem of proving how to improve the anti-inflammatory effect of the honey-refined fritillary and loquat syrup.
In order to achieve the technical purpose, the application adopts the following technical scheme:
in a first aspect, the application provides honey-refined fritillary and loquat syrup, which comprises the following components in parts by mass: 10-20 parts of honey, 60-80 parts of fritillaria cirrhosa, 200-300 parts of loquat leaf, 60-80 parts of platycodon grandiflorum, 0.4-1.5 parts of menthol, 40-60 parts of radix curcumae, 20-30 parts of green tea and 30-40 parts of liquorice.
Preferably, the mass ratio of the curcuma aromatica to the green tea is 6:2-3.
Preferably, the mass ratio of the curcuma aromatica to the honey is 6:1-2.
Preferably, the mass ratio of the liquorice to the loquat leaves is 4:20-25.
In a second aspect, there is provided the use of a honey-refined fritillary and loquat syrup as claimed in any one of claims 1 to 4 in anti-inflammatory foods and/or medicines.
Preferably, the honey refining type fritillary and loquat syrup is applied to reducing inflammatory leukocytes.
Preferably, the honey-refined fritillary and loquat syrup is applied to regulating the content of TNF-alpha in serum.
Preferably, the honey refining type fritillary and loquat syrup is applied to regulating the content of 1L-1 beta in serum.
The preparation method of the honey-refined fritillary and loquat syrup comprises the following steps:
S1, grinding fritillaria cirrhosa into powder, and adding 30-50% of ethanol aqueous solution for soaking to obtain leakage liquid;
S2, decocting other medicinal materials in the prescription for 12-36 hours, and filtering to obtain filtrate;
s3, concentrating the filtrate under reduced pressure to obtain medicinal material extract with the water content of 10-20%, adding honey and other auxiliary materials into the extract, heating again, and stirring and mixing uniformly to obtain the honey-refined fritillary and loquat syrup.
The anti-inflammatory effect of the syrups in examples and comparative examples was tested by animal experiments, the test mechanism was: the 15% ammonia water is directly sprayed to the pharyngeal portion of the rat, so that the pharyngeal portion tissue of the rat is dark red, matt and symptoms of increased mucous secretion are caused, the obvious acute congestion and swelling state is presented, and the modeling result of the acute pharyngitis model is prompted. In the acute pharyngitis state, the body produces an acute inflammatory response, which results in elevated levels of leukocytes and inflammatory mediators. The composition can be used for determining whether the composition has the effect of inhibiting the acute pharyngitis by comparing the white blood cell number in blood of an experimental group and a model group after the acute pharyngitis and the change of inflammatory mediators TNF-alpha and 1L-1 beta.
The beneficial effects of the application are as follows: the honey-refined fritillary and loquat syrup has obvious anti-inflammatory effect, can effectively inhibit the generation and release of inflammatory factors, reduces inflammatory symptoms, has no toxic or side effect, and has good taste and convenient use.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The application provides honey refining type fritillary and loquat syrup which comprises the following components in parts by weight: 10-20 parts of honey, 60-80 parts of fritillaria cirrhosa, 200-300 parts of loquat leaf, 60-80 parts of platycodon grandiflorum, 0.4-1.5 parts of menthol, 40-60 parts of radix curcumae, 20-30 parts of green tea and 30-40 parts of liquorice.
In the application, the functions of the components are as follows:
Honey: 1. the preparation method is used for preparing refined honey, the honey is heated to remove impurities and moisture, enzyme is destroyed, microorganisms are killed, and adhesive force is enhanced, so that a honey refined fritillary and loquat syrup preparation is formed; 2. relieving inflammatory response; first, honey contains abundant antioxidant substances, such as phenolic compounds and enzymes, which neutralize free radicals and reduce inflammatory reactions caused by oxidative stress. Secondly, the honey is rich in glucose oxidase, lactic acid kinase and other enzyme substances, so that the activity of an enzyme system in a human body can be enhanced, and anti-inflammatory reaction can be promoted. In addition, honey has some special anti-inflammatory molecules, and has the effect of directly inhibiting inflammatory cell activity. Meanwhile, the honey can also enhance immunity and improve the capability of human body in resisting inflammation; 3. synergistic with radix Curcumae to enhance antiinflammatory effects.
Bulbus Fritillariae Cirrhosae, folium Eriobotryae: has effects of clearing heat, moistening lung, eliminating phlegm, and relieving cough, and can be used for treating lung heat dry cough, dry cough with little phlegm, etc.
Licorice root: 1. inhibiting the generation and release of various inflammatory factors, and reducing inflammatory reaction; 2. the liquorice, the loquat leaves, the bulbus fritilariae and the like cooperate with each other to enhance the overall anti-inflammatory effect.
Radix Curcumae: 1. promoting blood circulation, relieving pain, activating qi-flowing, resolving stagnation, clearing heart fire, cooling blood, promoting bile flow, and eliminating jaundice; 2. the anti-inflammatory effect is synergistically enhanced by being combined with honey; 3. can be used in combination with green tea to synergistically enhance antiinflammatory effect.
Among the above components, 2 groups of synergies are involved to enhance the anti-inflammatory effect of honey-refined fritillary and loquat syrup, firstly, the curcuma aromatica and the honey are synergic to resist inflammation; and secondly, the curcuma aromatica and green tea are synergistic to resist inflammation. The reason is that the anti-inflammatory substances contained in the radix curcumae can cooperate with honey and green tea to improve the anti-inflammatory effect.
The synergic mechanism of the radix curcumae and the honey is as follows: the curcuma aromatica contains a large amount of curcumin, so that the curcuma aromatica can inhibit the generation of inflammatory mediators, reduce inflammatory reaction, regulate the related signal paths of inflammation, and the fructose, glucose and mineral substances in the honey can also play roles in resisting bacteria and diminishing inflammation; when the curcuma aromatica and the honey are combined, the anti-inflammatory effects of the curcuma aromatica and the honey can be mutually enhanced, on one hand, the components in the honey can promote the absorption of curcumin, and the anti-inflammatory effect of the curcuma aromatica and the honey is improved; on the other hand, curcumin can also enhance the anti-inflammatory effect of honey and further reduce the damage of inflammation to organisms.
The mechanism of the cooperation of the curcuma aromatica and the green tea is as follows: the curcuma aromatica contains a large amount of curcumin, the green tea contains a large amount of catechin, the catechin and the curcumin have antioxidation, free radicals can be removed, damage of oxidative stress to tissues can be reduced, the antioxidation can further inhibit inflammatory reaction, damage of inflammation to organisms can be reduced, the catechin and the curcumin can inhibit production of inflammatory factors such as cytokines, chemokines and the like, and promote production of anti-inflammatory factors such as interleukin-10, transforming growth factors and the like, so that the combined use can synergistically enhance the anti-inflammatory effect.
In some embodiments, the mass ratio of radix Curcumae to green tea is 6:2-3; the mass ratio of the radix curcumae to the honey is 6:1-2. Because the curcuma aromatica, green tea and honey all relate to synergistic and anti-inflammatory effects, the required curcuma aromatica is relatively large in usage amount.
In some embodiments, the mass ratio of the liquorice to the loquat leaves is 4:20-25, and the liquorice is excessive in dosage, so that the sweetness can be enhanced due to the existence of the honey, and the taste is poor; the dosage of the liquorice is too small, and the liquorice and the loquat leaves cannot play a role in synergic anti-inflammatory.
The preparation method of the honey-refined fritillary and loquat syrup comprises the following steps:
S1, crushing fritillaria cirrhosa, loquat leaves, platycodon grandiflorum, menthol, radix curcumae, green tea and liquorice into powder, and adding an extracting agent for soaking to obtain a mixture;
S2, filtering after the mixture is decocted to obtain filtrate;
s3, heating and concentrating the filtrate to obtain a concentrated solution, adding honey into the concentrated solution, and stirring and uniformly mixing to obtain the honey-refined fritillary and loquat syrup.
In some embodiments, the extractant is 30-50% ethanol water solution, and ethanol can be used for effectively extracting curcumin, pediatric flavin, etc.
In the step S2, the temperature of the decoction is 80-90 ℃, and the time of the decoction is 12-36h. In step S3, the heating temperature is 95-100 ℃. The decoction time in the step S2 is long, so that the decoction temperature is not too high, and the loss of active ingredients in the traditional Chinese medicine is avoided; the purpose of step S3 is to concentrate, evaporating water and ethanol at elevated temperature.
In some embodiments, the water content of the concentrate is 10-20%, the water content is too high, the syrup is too thick, it is difficult to swallow, the water content is too low, bacteria are easy to grow, and the preservation and transportation are not facilitated.
In the step S3, the honey is added and then heated again, so that impurities and moisture in the honey are removed, enzymes are destroyed, microorganisms are killed, and adhesive force is enhanced.
The application provides an application of honey-refined type fritillary and loquat syrup in anti-inflammatory food and/or medicine, and the honey-refined type fritillary and loquat syrup can be used as an additive component of food and medicine or can be directly taken.
Preferably, the honey refining type fritillary and loquat syrup is applied to reducing inflammatory leukocytes.
Preferably, the honey-refined fritillary and loquat syrup is applied to regulating the content of TNF-alpha in serum.
Preferably, the honey refining type fritillary and loquat syrup is applied to regulating the content of IL-1 beta in serum.
Preferably, the honey-refined fritillary and loquat syrup is applied to regulating the content of IgE in serum
Preferably, the honey-refined fritillary and loquat syrup is applied to regulating the content of IL-4 in serum
The present invention is further described below by way of specific examples.
Example 1
A honey-refined fritillary and loquat syrup comprises the following components in parts by weight: 20 parts of honey, 80 parts of fritillaria cirrhosa, 200 parts of loquat leaves, 80 parts of platycodon grandiflorum, 1.5 parts of menthol, 60 parts of radix curcumae, 30 parts of green tea and 40 parts of liquorice.
A preparation method of honey-refined fritillary and loquat syrup comprises the following steps:
S1, crushing fritillaria cirrhosa into powder, and adding 50% ethanol aqueous solution to soak for 24 hours to obtain percolate;
s2, decocting the mixture for 36 hours, and filtering to obtain filtrate;
S3, concentrating the filtrate under reduced pressure until a concentrated solution with the water content of 10% is obtained, adding honey into the concentrated solution, heating at 100 ℃, and stirring and mixing uniformly to obtain the honey-refined fritillary and loquat syrup.
Example 2
A honey-refined loquat leaf and Sichuan fritillary bulb syrup is the same as in example 1 except that the amount of turmeric root-tuber is 40 parts.
Example 3
A honey-refined syrup of Bulbus Fritillariae Cirrhosae and Eriobotrya japonica is the same as in example 1 except that Glycyrrhrizae radix is used in an amount of 20 parts.
Example 4
A honey-refined fritillary and loquat syrup comprises the following components in parts by weight: 10 parts of honey, 60 parts of fritillaria cirrhosa, 300 parts of loquat leaves, 60 parts of platycodon grandiflorum, 1 part of menthol, 50 parts of radix curcumae, 20 parts of green tea and 30 parts of liquorice.
Comparative example 1
A honey-refined loquat leaf and Sichuan fritillary bulb syrup is the same as in example 1 except that the syrup does not contain radix Curcumae and the honey is 80 parts.
Comparative example 2
A syrup of Bulbus Fritillariae Cirrhosae and Eriobotrya japonica is prepared in the same manner as in example 1 except that Mel is not included, and radix Curcumae is used in an amount of 80 parts.
Comparative example 3
A honey-refined loquat leaf and Sichuan fritillary bulb syrup is the same as in example 1 except that green tea is not included, and the amount of radix Curcumae is 90 parts.
Comparative example 4
A honey-refined loquat leaf and Sichuan fritillary bulb syrup is the same as in example 1 except that the turmeric root-tuber is not included and the green tea is used in an amount of 90 parts.
Comparative example 5
A syrup of Bulbus Fritillariae Cirrhosae and Eriobotrya japonica was prepared in the same manner as in example 1 except that radix Curcumae and Mel were not included.
Comparative example 6
A syrup of fritillary and loquat leaf is the same as in example 1 except that the syrup does not contain radix Curcumae nor green tea.
Evaluation test
The anti-inflammatory effect of the syrups in examples and comparative examples was tested by animal experiments, the test mechanism was: the 15% ammonia water is directly sprayed to the pharyngeal portion of the rat, so that the pharyngeal portion tissue of the rat is dark red, matt and symptoms of increased mucous secretion are caused, the obvious acute congestion and swelling state is presented, and the modeling result of the acute pharyngitis model is prompted. In the acute pharyngitis state, the body produces an acute inflammatory response, which results in elevated levels of leukocytes and inflammatory mediators. The composition can be used for determining whether the composition has the effect of inhibiting the acute pharyngitis by comparing the white blood cell number in blood of an experimental group and a model group after the acute pharyngitis and the change of inflammatory mediators TNF-alpha and 1L-1 beta.
Grouping animals: the clean SD rats, weighing 180-220 g, were randomly divided into 6 groups, namely a blank group, a model group (ammonia molding), a example 1 group, a example 2 group, a example 3 group, a comparative example 1 group, a comparative example 2 group, a comparative example 3 group, a comparative example 4 group, a comparative example 5 group, and a comparative example 6 group, each group of 10 animals.
The specific administration method is as follows: blank group, rats were given equal volume of distilled water 1 time per day for continuous gavage for 5 days; model group, the rats are given equal volume of distilled water for 1 time each day, and the rats are continuously irrigated for 5 days; examples, comparative example group: rats were given 1.2g/kg of the composition each daily and 1 time at 10mL/kg of the composition were gavaged for 5 days.
And (3) testing: after 0.5 hour of administration on the fifth day, whole blood of the rats was collected, a part thereof was subjected to blood conventional leukocyte detection, and a part thereof was subjected to serum extraction, and the levels of TNF- α, IL-1 β, igE and IL-4 in the serum of the rats were detected by using a commercially available ELISA kit.
The average value of each group was calculated, and the results of the white blood cell count, TNF-. Alpha., IL-1β, igE, and IL-4 in serum are shown in Table 1.
Table 1 anti-inflammatory test evaluation results
As can be seen from Table 1, the syrups in examples and comparative examples have a certain anti-inflammatory effect, wherein the anti-inflammatory effect of the syrup of honey-refined type fritillary and loquat is superior to that of the syrup of comparative example. With reference to comparative example 5, honey and radix Curcumae were used in example 1, and only one of the components was used in comparative example 1 and comparative example 2, but the sum of the decrease in white blood cells in comparative example 1 and comparative example 2 was smaller than that in example 1, which indicates that honey and radix Curcumae synergistically reduced the white blood cell number to achieve synergistic anti-inflammatory effect. Similarly, the data of comparative examples 1, 3 and 4, using comparative example 6 as a reference value, show that radix Curcumae and green tea also have synergistic effect in enhancing anti-inflammatory effect.
The present invention is not limited to the above-mentioned embodiments, and any changes or substitutions that can be easily understood by those skilled in the art within the technical scope of the present invention are intended to be included in the scope of the present invention.
Claims (8)
1. The honey refining type fritillary and loquat syrup is characterized by comprising the following components in parts by weight: 10-20 parts of honey, 60-80 parts of fritillaria cirrhosa, 200-300 parts of loquat leaf, 60-80 parts of platycodon grandiflorum, 0.4-1.5 parts of menthol, 40-60 parts of radix curcumae, 20-30 parts of green tea and 30-40 parts of liquorice.
2. The honey-refined fritillary and loquat syrup as claimed in claim 1, wherein the mass ratio of the curcuma aromatica to the green tea is 6:2-3.
3. The honey-refined fritillary and loquat syrup as claimed in claim 1, wherein the mass ratio of the curcuma aromatica to the honey is 6:1-2.
4. The honey-refined type fritillary and loquat syrup as claimed in claim 1, wherein the mass ratio of the liquorice to the loquat leaf is 4:20-25.
5. Use of the honey-refined fritillary and loquat syrup as claimed in any one of claims 1 to 4 in anti-inflammatory foods and/or medicines.
6. The use according to claim 5, wherein the honey-refined fritillary and loquat syrup is used for reducing inflammatory leukocytes.
7. The use according to claim 5, wherein the honey-refined fritillary and loquat syrup is used for regulating TNF-alpha content in serum.
8. The use according to claim 5, wherein the honey-refined fritillary and loquat syrup is used for regulating the content of 1L-1 beta in serum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410144238.5A CN118059201A (en) | 2024-02-01 | 2024-02-01 | Anti-inflammatory medicinal effect application of honey refining type fritillary and loquat syrup preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410144238.5A CN118059201A (en) | 2024-02-01 | 2024-02-01 | Anti-inflammatory medicinal effect application of honey refining type fritillary and loquat syrup preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118059201A true CN118059201A (en) | 2024-05-24 |
Family
ID=91096370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410144238.5A Pending CN118059201A (en) | 2024-02-01 | 2024-02-01 | Anti-inflammatory medicinal effect application of honey refining type fritillary and loquat syrup preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118059201A (en) |
-
2024
- 2024-02-01 CN CN202410144238.5A patent/CN118059201A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103230012B (en) | Honeycomb essence buccal tablet and preparation process thereof | |
| US10987396B2 (en) | Composition for improving internal circulation and delaying aging and application thereof | |
| KR20180013397A (en) | Food composition comprising the mixed herbal extract as an active ingredient | |
| CN114271502A (en) | Clam peptide compound for protecting cardiovascular system and kidney and application thereof | |
| CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
| CN104667135A (en) | Pharmaceutical composition and health care product and preparation method | |
| WO2016202183A1 (en) | Formula dog food and preparation method therefor | |
| CN116941700B (en) | Throat-clearing and throat-moistening candy rich in vitamin C and preparation method thereof | |
| CN105941816A (en) | Chewing gum with healthcare functions and cyclocarya paliurus | |
| CN1907374A (en) | Chinese medicinal composition for treating oral disease | |
| CN106070783A (en) | A kind of production technology of Semen Coicis damp eliminating tea | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| CN104431061A (en) | Tea with functions of reducing blood sugar and losing weight and production method thereof | |
| CN118059201A (en) | Anti-inflammatory medicinal effect application of honey refining type fritillary and loquat syrup preparation | |
| CN111298020B (en) | Traditional Chinese medicine composition with anti-fatigue effect and preparation method and application thereof | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| CN110916036A (en) | Liquor and preparation method thereof | |
| CN103843902B (en) | A kind of liquid diary product containing the root of kudzu vine and preparation method thereof | |
| CN111888431A (en) | Composition for treating diabetes and preparation method thereof | |
| CN104886252A (en) | Compound traditional Chinese medicine antialcoholic yogurt and preparation technology thereof | |
| CN107693590B (en) | Composition with health care function and preparation method and application thereof | |
| KR102649426B1 (en) | Oral spray composition | |
| CN115006489B (en) | Fermented rhizoma polygonati extract with blood pressure reducing effect, preparation method and application | |
| CN116036174B (en) | Medicine for treating pulmonary nodules and preparation method thereof | |
| CN116211993B (en) | Composition for treating senile chronic disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |